EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical endpoints special session, ISCEV 2025, Utrecht

R Hamilton, D Birch, K Stingl, K Fujinami, K Holopigian, C J F Boon, J Moseley, J J McAnany, A V Cideciyan, M M van Genderen

Documenta Ophthalmologica · 2026-08 · 153 (1) · 3-11

DOI: 10.1007/s10633-026-10108-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Documenta Ophthalmologica, online erschienen am 20.05.2026. Verfasst von R Hamilton und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Physics & Bioengineering, Royal Hospital for Children, Glasgow, UK. Hauptthemen laut MEDLINE: Retinal Diseases, Clinical Trials as Topic, Endpoint Determination, Societies, Medical. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation Fighting Blindness, Universitätsklinikum Tübingen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This report summarises the Clinical Endpoints Special Session held during the 62nd annual symposium of the International Society for Clinical Electrophysiology of Vision (ISCEV), convened at Tivoli Vredenburg, Utrecht, The Netherlands. The session brought together clinicians, regulators, industry representatives, and a patient voice to consider the state of clinical endpoints in trials for inherited retinal disorders (IRDs). Discussions covered the adequacy of current endpoints, challenges of disease heterogeneity, regulatory expectations, operational feasibility, and the perspectives of patients. The session highlighted the need to anchor emerging endpoints to clinically meaningful outcomes and to minimise assessment burdens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retinal DiseasesClinical Trials as TopicEndpoint DeterminationSocieties, MedicalHumans

Stichwörter der Autor:innen

Clinical endpointsClinical trialsPatients perspectiveRetinal dystrophies

Autor:innen und Institutionen

  • Department of Clinical Physics & Bioengineering, Royal Hospital for Children, Glasgow, UK.
  • College of Medicine, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.
  • Retina Foundation of the Southwest, Dallas, USA.
  • University Eye Hospital, Center for Ophthalmology, University of Tübingen, Elfriede-Aulhorn-Straße 7, 72076, Tübingen, Germany. Katarina.Stingl@med.uni-tuebingen.de.
  • Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • University College London Institute of Ophthalmology, London, UK.

Förderung

  • Foundation Fighting Blindness
  • Universitätsklinikum Tübingen

Zitieren

APA

Hamilton, R., Birch, D., Stingl, K., Fujinami, K., Holopigian, K., Boon, C. J. F., Moseley, J., McAnany, J. J., Cideciyan, A. V., & van Genderen, M. M. (2026). Clinical endpoints special session, ISCEV 2025, Utrecht. Documenta Ophthalmologica, 153(1), 3-11. https://doi.org/10.1007/s10633-026-10108-8

Vancouver

Hamilton R, Birch D, Stingl K, Fujinami K, Holopigian K, Boon CJF, et al. Clinical endpoints special session, ISCEV 2025, Utrecht. Documenta Ophthalmologica. 2026;153(1):3-11. doi:10.1007/s10633-026-10108-8

BibTeX
@article{Hamilton2026,
  author = {Hamilton, R and Birch, D and Stingl, K and Fujinami, K and Holopigian, K and Boon, C J F and Moseley, J and McAnany, J J and Cideciyan, A V and van Genderen, M M},
  title = {Clinical endpoints special session, ISCEV 2025, Utrecht},
  journal = {Documenta Ophthalmologica},
  year = {2026},
  volume = {153},
  number = {1},
  pages = {3--11},
  doi = {10.1007/s10633-026-10108-8}
}
Kostenlos starten →